Therapy Areas: Cardiovascular
15 November 2018 - - Anglo-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF) has received positive full results from the DECLARE-TIMI 58 cardiovascular outcomes trial for Farxiga (dapagliflozin)...
15 November 2018 - - French research and development company Valbiotis has expanded the application for Valedia to NASH2prevention, the company said.

This new field of application is base...
15 November 2018 - Cardiovascular surgery company Terumo Cardiovascular Group revealed on Wednesday the receipt of the US Food and Drug Administration's (FDA) 510(k) clearance for the CDI Blood P...
14 November 2018 - AstraZeneca Plc (LSE:AZN), a global, science-led biopharmaceutical company, announced on Tuesday an agreement to sell US rights to Synagis (palivizumab), used for the prevention of ...
13 November 2018 - Biopharmaceutical company PolyPid Ltd said on Monday that it will proceed with its phase 3 clinical trial of its lead asset D-PLEX[100] for the prevention of post-cardiac surgery st...
8 November 2018 - Myovant Sciences Ltd (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for women's health and endocrine dis...
Related Headlines